SynAct Pharma AB
STO:SYNACT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Xpro India Ltd
NSE:XPROINDIA
|
IN |
|
R
|
RVRC Holding AB
STO:RVRC
|
SE |
|
Shenzhen Etmade Automatic Equipment Co Ltd
SZSE:300812
|
CN |
|
Hormel Foods Corp
NYSE:HRL
|
US |
|
INKON Life Technology Co Ltd
SZSE:300143
|
CN |
SynAct Pharma AB
Total Current Assets
SynAct Pharma AB
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
SynAct Pharma AB
STO:SYNACT
|
Total Current Assets
kr71.3m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
27%
|
CAGR 10-Years
N/A
|
|
|
Biogaia AB
STO:BIOG B
|
Total Current Assets
kr1.2B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
Bonesupport Holding AB
STO:BONEX
|
Total Current Assets
kr796.7m
|
CAGR 3-Years
33%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Vitrolife AB
STO:VITR
|
Total Current Assets
kr2.1B
|
CAGR 3-Years
10%
|
CAGR 5-Years
8%
|
CAGR 10-Years
18%
|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Total Current Assets
kr14.5B
|
CAGR 3-Years
9%
|
CAGR 5-Years
12%
|
CAGR 10-Years
20%
|
|
|
BioArctic AB
STO:BIOA B
|
Total Current Assets
kr2.5B
|
CAGR 3-Years
45%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
SynAct Pharma AB
Glance View
SynAct Pharma AB engages in the development of pharmaceutical drugs for the treatment of inflammatory diseases. The company is headquartered in Lund, Skane. The company went IPO on 2016-07-11. The firm is located in Lund, Sweden. The company develops medicines for acute impairment in inflammatory diseases. The firm's drug candidate AP1189 is intended for the treatment of arthritis including psoriasis arthritis.
See Also
What is SynAct Pharma AB's Total Current Assets?
Total Current Assets
71.3m
SEK
Based on the financial report for Dec 31, 2025, SynAct Pharma AB's Total Current Assets amounts to 71.3m SEK.
What is SynAct Pharma AB's Total Current Assets growth rate?
Total Current Assets CAGR 5Y
27%
Over the last year, the Total Current Assets growth was -24%. The average annual Total Current Assets growth rates for SynAct Pharma AB have been -20% over the past three years , 27% over the past five years .
